Mount Sinai Scientist Recognized for Outstanding Basic Research Contributions to Neuropsychopharmacology
Scott Russo, PhD, Professor of Neuroscience and Director of the Center for Affective Neuroscience within the Nash Family Department of Neuroscience and The Friedman Brain Institute at Mount Sinai, has been awarded the 2019 Daniel H. Efron Research Award from the American College of Neuropsychopharmacology (ACNP). The award is given in recognition of outstanding basic research contributions to neuropsychopharmacology, the study of the neural mechanisms by which drugs affect behavior. Dr. Russo was presented the award at the 58th Annual Meeting of the ACNP in Orlando, Florida.
Dr. Russo is recognized internationally for his contributions to the understanding of neural and immunological mechanisms underlying neuropsychiatric disorders such as depression and anxiety. His translational studies of depression-like behaviors in rodent models have identified novel disease mechanisms in depressed humans. The Russo Lab at Mount Sinai uses a broad array of tools to gain insight into how the brain and body adapt to stress and how a failure in adaptation may result in pathological behaviors associated with depression and anxiety.
Over the past decade, Dr. Russo has made outstanding contributions to psychopharmacology and the molecular understanding of neuropsychiatric disease. He has received numerous honors and awards, which include the Johnson & Johnson/IMHRO Rising Star in Translational Research and being named a Kavil National Academy of Science Frontiers Fellow.
Dr. Russo is the latest in a long line of Mount Sinai winners of ACNP’s prestigious Efron Award, including:
- Kenneth L. Davis, MD, President and Chief Executive Officer of the Mount Sinai Health System
- Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and President for Academic Affairs of the Mount Sinai Health System
- Eric J. Nestler, MD, PhD, Dean for Academic and Scientific Affairs and Director of The Friedman Brain Institute
- Joseph D. Buxbaum, PhD, Professor of Psychiatry, Genetics and Genomic Sciences, and Neuroscience, and Director of The Seaver Autism Center for Research and Treatment
- Paul J. Kenny, PhD, Ward-Coleman Professor and Chair of the Nash Family Department of Neuroscience
“This is testimony to the dominant role Mount Sinai has played in psychiatric neuroscience over a generation,” said Dr. Nestler. “Dr. Russo’s highly innovative and transformative research program is revealing fundamentally novel mechanisms of stress, depression, and resilience, and promises new treatments for several stress-related illnesses.”
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.